Department of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Department of Ophthalmology and Visual Sciences, West Virginia University, Morgantown, West Virginia, USA.
Hum Gene Ther. 2022 Jul;33(13-14):708-718. doi: 10.1089/hum.2021.298. Epub 2022 May 16.
Blue cone monochromacy (BCM) is a congenital vision disorder affecting both middle-wavelength (M) and long-wavelength (L) cone photoreceptors of the human retina. BCM results from abolished expression of green and red light-sensitive visual pigments expressed in M- and L-cones, respectively. Previously, we showed that gene augmentation therapy to deliver either human L- or M-opsin rescues dorsal M-opsin dominant cone photoreceptors structurally and functionally in treated M-opsin knockout () mice. Although mice represent a disease model for BCM patients with deletion mutations, at the cellular level, dorsal cones of mice still express low levels of S-opsin, which are different from L- and M-cones of BCM patients carrying a congenital opsin deletion. To determine whether BCM cones lacking complete opsin expression from birth would benefit from AAV-mediated gene therapy, we evaluated the outcome of gene therapy, and determined the therapeutic window and longevity of rescue in a mouse model lacking both M- and S-opsin (). Our data show that cones of mice are viable at younger ages but undergo rapid degeneration. AAV-mediated expression of human L-opsin promoted cone outer segment regeneration and rescued cone-mediated function when mice were injected subretinally at 2 months of age or younger. Cone-mediated function and visually guided behavior were maintained for at least 8 months post-treatment. However, when mice were treated at 5 and 7 months of age, the chance and effectiveness of rescue was significantly reduced, although cones were still present in the retina. Crossing mice with proteasomal activity reporter mice (Ub-GFP) did not reveal GFP accumulation in cones eliminating impaired degradation of ubiquitinated proteins as stress factor contributing to cone loss. Our results demonstrate that AAV-mediated gene augmentation therapy can rescue cone structure and function in a mouse model with a congenital opsin deletion, but also emphasize the importance that early intervention is crucial for successful therapy.
蓝色锥体细胞单色性(BCM)是一种先天性视觉障碍,影响人类视网膜的中波(M)和长波(L)锥体细胞。BCM 是由于分别在 M-和 L-锥体中表达的绿光和红光敏感视色素表达被废除引起的。以前,我们表明,基因增强疗法可将人 L-或 M-视蛋白递送至处理的 M-视蛋白敲除()小鼠中,在结构和功能上分别挽救背侧 M-视蛋白优势锥体光感受器。尽管 小鼠代表具有缺失突变的 BCM 患者的疾病模型,但在细胞水平上, 小鼠的背侧锥体仍表达低水平的 S-视蛋白,这与携带先天性视蛋白缺失的 L-和 M-锥体的 BCM 患者的 L-和 M-锥体不同。为了确定从出生起就缺乏完整视蛋白表达的 BCM 锥体是否会受益于 AAV 介导的基因治疗,我们评估了基因治疗的结果,并确定了在缺乏 M-和 S-视蛋白的小鼠模型中()的治疗窗口和挽救的寿命。我们的数据表明, 小鼠的锥体在较年轻时是有活力的,但会迅速退化。当小鼠在 2 个月龄或更小时通过视网膜下注射 AAV 介导表达人 L-视蛋白时,可促进锥体外段再生并挽救锥体介导的功能。在治疗后至少 8 个月内,仍维持着锥体介导的功能和视觉引导行为。但是,当小鼠在 5 个月和 7 个月大时进行治疗时,挽救的机会和效果明显降低,尽管视网膜中仍存在锥体。将 小鼠与蛋白酶体活性报告小鼠(Ub-GFP)杂交并没有在 锥体中发现 GFP 积累,从而消除了作为导致锥体丢失的应激因素的泛素化蛋白降解受损。我们的结果表明,AAV 介导的基因增强疗法可以挽救先天性视蛋白缺失的小鼠模型中的锥体结构和功能,但也强调了早期干预对于成功治疗的重要性。